GET DAILY SIGNALSLineage Cell Therapeutics (LCTX): Cell Therapies Targeting Degenerative Conditions
Key Takeaways
- Lineage Cell Therapeutics is a clinical-stage biotechnology company developing "off-the-shelf" allogeneic cell replacement therapies for serious medical conditions.
- The company is headquartered in Carlsbad, California, and was originally incorporated in 1990 under the name BioTime, Inc. before rebranding as Lineage in August 2019.
- Its pipeline is built around its proprietary AlloSCOPE platform and includes programs targeting dry age-related macular degeneration (AMD), spinal cord injuries, hearing loss, and other degenerative diseases.
- Lineage's lead program, OpRegen, is partnered with Roche and Genentech, giving the company a notable pharmaceutical collaboration for a clinical-stage firm.
- As a pre-revenue-stage biotechnology company with modest collaboration income, Lineage carries the execution, clinical, and financing risks common to early-stage drug developers.
Company Background
LCTX represents Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology firm listed on the NYSE American exchange (and also traded on the Tel Aviv Stock Exchange). The company centers its efforts on regenerative medicine through cell replacement therapies aimed at restoring or supporting cells that have become absent or dysfunctional due to degenerative disease, aging, or traumatic injury. Investors track LCTX because its pipeline targets sizable underserved markets in ophthalmology and neurology, and its lead program carries backing from one of the world's largest pharmaceutical companies. To get a broader view of similar biotech plays, I ran a quick screen with Tickeron’s AI Screener.
Pipeline and Technology Platform
Lineage Cell Therapeutics was incorporated in 1990 and was formerly known as BioTime, Inc.; it adopted its current name in August 2019, changing its ticker from BTX to LCTX. The company is headquartered in Carlsbad, California, and employs roughly 70–80 people.
At the center of Lineage's business model is its proprietary cell-based technology platform, AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering). Using directed differentiation protocols applied to established, well-characterized pluripotent cell lines, the company manufactures specialized human cells designed to resemble cells found naturally in the body. Because these therapies are allogeneic — meaning the cells come from a universal donor source rather than from the patient — they can be produced in advance and stored, potentially enabling "off-the-shelf" treatment.
Lineage's pipeline includes several programs across ophthalmology and neurology:
- OpRegen — a retinal pigment epithelial (RPE) cell replacement therapy in Phase 2a development for geographic atrophy secondary to age-related macular degeneration (AMD), developed under a worldwide collaboration with Roche and Genentech.
- OPC1 — an oligodendrocyte progenitor cell therapy in Phase 1/2a development for spinal cord injuries.
- ReSonance (ANP1) — an auditory neuronal progenitor cell therapy in development for auditory neuropathy and other hearing conditions.
- PNC1 — a photoreceptor neural cell therapy being developed for vision loss.
- RND1 — a hypoimmune induced pluripotent stem cell (iPSC) line under development through a gene-editing partnership.
As a clinical-stage company, Lineage generates limited revenue, primarily from collaborations and grants rather than product sales. Its business model depends on advancing programs through clinical trials and securing partnerships, milestones, and royalty arrangements. The Roche/Genentech collaboration on OpRegen is the most significant of these partnerships, providing both validation and non-dilutive funding.
What Draws Investors to LCTX
Lineage attracts investor attention primarily because of the scale of the medical problems its therapies target and the strength of its lead collaboration. Age-related macular degeneration and spinal cord injury represent large patient populations with limited treatment options, and a successful cell replacement therapy could address significant unmet medical needs.
The company's allogeneic, "off-the-shelf" approach is also a key differentiator. Unlike autologous cell therapies, which are manufactured from a patient's own cells, allogeneic products can be produced in batches and used across many patients, potentially reducing cost and improving scalability. Lineage's in-house manufacturing capabilities and its track record of producing clinical-grade cell lots are positioned as competitive advantages in a field where manufacturing expertise is a meaningful barrier to entry.
The Roche/Genentech partnership provides external validation of the platform and reduces some of the financial burden of advancing OpRegen, while leaving Lineage with a potential path to milestone payments and royalties. For investors, this combination of a differentiated technology platform, a broad pipeline, and a large pharmaceutical collaboration forms the core of Lineage's long-term investment thesis.
Key Risks to Consider
Investing in Lineage carries the risks typical of clinical-stage biotechnology. The company's therapies are still in clinical or preclinical development, and there is no guarantee that any program will demonstrate sufficient safety or efficacy to reach regulatory approval or commercialization.
Lineage's financial profile reflects its early stage: it has historically generated modest revenue and recorded net losses, meaning it may need to raise additional capital through equity offerings, partnerships, or debt, which could dilute existing shareholders. The company's fortunes are also closely tied to its collaboration with Roche and Genentech; changes to that partnership, or setbacks in the OpRegen program, could have a material impact.
Additional considerations include intense competition in regenerative medicine and ophthalmology, the regulatory complexity of cell-based therapies, and the clinical and manufacturing risks inherent in developing complex biologics. Investors should understand that these factors make Lineage a higher-risk, longer-horizon investment relative to more established companies.
Enhancing Research with AI Tools
In my own analysis, I often rely on Tickeron’s AI Screener to cross-check industry comparisons and identify patterns across the biotech sector. The platform lets users apply technical indicators, fundamentals, volatility filters, AI-generated signals, and customizable criteria to narrow down thousands of stocks and ETFs efficiently. This helps streamline the process of spotting ideas that align with specific strategies without sifting through everything manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for LCTX turns positive, indicating new upward trend
LCTX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 118 similar instances where the indicator turned positive. In 96 of the 118 cases, the stock moved higher in the following days. The odds of a move higher are at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LCTX just turned positive on October 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
LCTX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +4.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 158 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.482). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
Industry Biotechnology
Advertisement